Jasper Therapeutics(US:JSPR)2025-05-12 20:05Financial Performance - Jasper reported a net loss of $21.2 million for Q1 2025, with a net loss per share of $1.41, compared to a net loss of $13.7 million in Q1 2024[6][10]. - Total operating expenses for Q1 2025 were $21.8 million, compared to $15.1 million in Q1 2024[6][10]. - Cash and cash equivalents as of March 31, 2025, totaled $48.8 million, a decrease from $71.6 million at the end of 2024[6][12]. - Total current assets decreased to $53.2 million as of March 31, 2025, from $75.8 million at the end of 2024[6][12]. - Total liabilities decreased to $15.4 million as of March 31, 2025, compared to $18.2 million at the end of 2024[6][12]. Research and Development - Research and development expenses for the three months ended March 31, 2025, were $16.2 million, up from $10.3 million in the same period last year[6][10]. - The BEACON study in chronic spontaneous urticaria (CSU) is expected to provide mid-year data updates in Q3 2025, which will inform the final dose selection for the planned Phase 2b study[2][3]. - Enrollment in the SPOTLIGHT Phase 1b/2a study for cold urticaria and symptomatic dermographism has been completed, with data expected to be reported in June 2025[3]. - The ETESIAN Phase 1b/2a study for allergic asthma continues to enroll patients, with initial data anticipated in the second half of 2025[6][3]. - The company plans to commence the Phase 2b operationally-adaptive study in the second half of 2025, pending data from ongoing studies[3][2].